The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.
Gerald Steven Falchook
No relevant relationships to disclose
Jonathan Wade Goldman
No relevant relationships to disclose
Jayesh Desai
Consultant or Advisory Role - Ceres Oncology/Vegenics
Research Funding - Roche
Ian Leitch
Employment or Leadership Position - Ceres Oncology/Vegenics
Stock Ownership - Ceres Oncology/Vegenics
David S. Hong
No relevant relationships to disclose
Vivek Subbiah
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Lee S. Rosen
Research Funding - Ceres Oncology/Vegenics